Colorectal Cancer

The panel reviews the different settings in colorectal cancer where ctDNA is being investigated as a tool for treatment and monitoring.

Dr Daniel H. Ahn explains the logistical concerns of ctDNA testing in colorectal cancer.

Aparna Parikh, MD, MS, defines circulating tumor DNA (ctDNA) and the use of ctDNA assays in colorectal cancer.

The panel discusses other emerging biomarkers for monitoring patient response to therapy for colorectal cancer.

Dr Aparna Parikh explains minimal residual disease (MRD) in colorectal cancer and the logistical challenges of MRD testing.

Dr Stacey A. Cohen discusses how she typically monitors patients with stage II and III colorectal cancer during and after adjuvant therapy.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, describe the challenges of deciding which patients with colorectal cancer should receive adjuvant therapy, and the risk of over- and under-treatment in later stages.

Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.

Aparna Parikh, MD, MS, details when she would recommend adjuvant chemotherapy to patients with similar presentations of colorectal cancer.

Tanios S. Bekaii-Saab, MD, presents a patient scenario of a 64-year-old man with stage 2 (pT3N0) colon cancer to the panel for discussion.

Expert oncologists review key updates regarding metastatic colorectal cancer from recent meetings and discuss their implications on real-world clinical practice.

Findings from the phase 3 BREAKWATER study indicate that encorafenib plus cetuximab and chemotherapy produces activity and is well-tolerated in metastatic colorectal cancer harboring BRAF V600E mutations.

Findings from the phase 2 MOUNTAINEER trial indicate that HER2 scoring algorithms may help in identifying which patients are suitable to receive tucatinib plus trastuzumab for metastatic colorectal cancer.

Findings from the phase 3 SUNLIGHT study highlight favorable overall survival and disease control rates with the use of bevacizumab plus trifluridine and tipiracil in metastatic colorectal cancer.

Novel, personalized, tumor-informed brPROPHET technology can assess molecular residual disease with greater sensitivity than other assays, according to initial data.

Molecular responders by G360 response algorithm with advanced colorectal cancer appear to have significantly lengthened time on treatment and overall survival with all regimens vs patients who did not respond.

The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.

An expert from Natera indicates that post-operative ctDNA level may have strong prognostic and predictive value in patients with resectable colorectal cancer.

The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.

A stool-based, non-invasive, at-home colorectal cancer and advanced adenoma test showed a strong ability to detect disease, according to updated trial results.

Elle Charnisky, a patient with HER2+ metastatic colorectal cancer, and Deanne Griffie, a nurse practitioner, share advice for patients and caregivers living with HER2+ mCRC.

Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.

Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.

Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.

Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.

Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.

The FDA granted breakthrough therapy designation to adagrasib plus cetuximab for patients with KRAS G12C–mutated advanced colorectal cancer based on findings from the phase 1b cohort of the KRYSTAL-1 trial.

Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.

The findings, according to a third-party expert, suggest there’s no benefit to the use of trifluridine and tipiracil alone in earlier lines of therapy for the treatment of colon cancer.

John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.